Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

Despite the initial successes of immunotherapy, there is an urgent clinical need for
molecular assays that identify patients more likely to respond. Here, we report that …

Various recent studies have focused on analyzing tumor genetic material released into the
blood stream, known as circulating tumor DNA (ctDNA). Herein, we describe current …

Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …